JP2011506511A - 副作用を軽減または防止するためのボツリヌス菌毒素複合体の神経毒成分の使用 - Google Patents
副作用を軽減または防止するためのボツリヌス菌毒素複合体の神経毒成分の使用 Download PDFInfo
- Publication number
- JP2011506511A JP2011506511A JP2010538453A JP2010538453A JP2011506511A JP 2011506511 A JP2011506511 A JP 2011506511A JP 2010538453 A JP2010538453 A JP 2010538453A JP 2010538453 A JP2010538453 A JP 2010538453A JP 2011506511 A JP2011506511 A JP 2011506511A
- Authority
- JP
- Japan
- Prior art keywords
- muscle
- muscles
- botulinum toxin
- component
- neurotoxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 82
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 74
- 239000002581 neurotoxin Substances 0.000 title claims abstract description 67
- 231100000618 neurotoxin Toxicity 0.000 title claims abstract description 67
- 101710138657 Neurotoxin Proteins 0.000 title claims abstract description 65
- 230000000694 effects Effects 0.000 title claims abstract description 40
- 241000193155 Clostridium botulinum Species 0.000 title claims abstract description 22
- 210000003205 muscle Anatomy 0.000 claims abstract description 113
- 239000002537 cosmetic Substances 0.000 claims abstract description 50
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 30
- 241000282414 Homo sapiens Species 0.000 claims abstract description 23
- 241001465754 Metazoa Species 0.000 claims abstract description 23
- 201000010099 disease Diseases 0.000 claims abstract description 17
- 208000035475 disorder Diseases 0.000 claims abstract description 13
- 210000003499 exocrine gland Anatomy 0.000 claims abstract description 13
- 210000000887 face Anatomy 0.000 claims abstract description 11
- 230000001713 cholinergic effect Effects 0.000 claims abstract description 10
- 230000030214 innervation Effects 0.000 claims abstract description 8
- 241000282412 Homo Species 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims description 62
- 231100000189 neurotoxic Toxicity 0.000 claims description 53
- 230000002887 neurotoxic effect Effects 0.000 claims description 53
- 239000007924 injection Substances 0.000 claims description 47
- 238000002347 injection Methods 0.000 claims description 47
- 230000001815 facial effect Effects 0.000 claims description 44
- 206010040954 Skin wrinkling Diseases 0.000 claims description 32
- 230000037303 wrinkles Effects 0.000 claims description 30
- 208000002193 Pain Diseases 0.000 claims description 28
- 210000004709 eyebrow Anatomy 0.000 claims description 21
- 208000008454 Hyperhidrosis Diseases 0.000 claims description 18
- 206010052904 Musculoskeletal stiffness Diseases 0.000 claims description 15
- 210000000744 eyelid Anatomy 0.000 claims description 15
- 210000001508 eye Anatomy 0.000 claims description 13
- 208000034656 Contusions Diseases 0.000 claims description 12
- 206010041349 Somnolence Diseases 0.000 claims description 10
- 206010025482 malaise Diseases 0.000 claims description 10
- 230000009519 contusion Effects 0.000 claims description 9
- 206010037660 Pyrexia Diseases 0.000 claims description 8
- 230000037315 hyperhidrosis Effects 0.000 claims description 8
- 230000035900 sweating Effects 0.000 claims description 8
- 210000001097 facial muscle Anatomy 0.000 claims description 7
- 210000001061 forehead Anatomy 0.000 claims description 7
- 210000003813 thumb Anatomy 0.000 claims description 7
- 208000010201 Exanthema Diseases 0.000 claims description 6
- 208000032140 Sleepiness Diseases 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 6
- 201000005884 exanthem Diseases 0.000 claims description 6
- 210000004907 gland Anatomy 0.000 claims description 6
- 210000003128 head Anatomy 0.000 claims description 6
- 206010037844 rash Diseases 0.000 claims description 6
- 210000001364 upper extremity Anatomy 0.000 claims description 6
- 208000019505 Deglutition disease Diseases 0.000 claims description 5
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 5
- 206010013774 Dry eye Diseases 0.000 claims description 5
- 206010015946 Eye irritation Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010022004 Influenza like illness Diseases 0.000 claims description 5
- 206010023644 Lacrimation increased Diseases 0.000 claims description 5
- 206010028813 Nausea Diseases 0.000 claims description 5
- 208000005141 Otitis Diseases 0.000 claims description 5
- 208000003251 Pruritus Diseases 0.000 claims description 5
- 206010046543 Urinary incontinence Diseases 0.000 claims description 5
- 210000004087 cornea Anatomy 0.000 claims description 5
- 208000002173 dizziness Diseases 0.000 claims description 5
- 208000019258 ear infection Diseases 0.000 claims description 5
- 231100000013 eye irritation Toxicity 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 230000003447 ipsilateral effect Effects 0.000 claims description 5
- 230000004317 lacrimation Effects 0.000 claims description 5
- 230000008693 nausea Effects 0.000 claims description 5
- 231100000862 numbness Toxicity 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- 230000035945 sensitivity Effects 0.000 claims description 5
- 230000009747 swallowing Effects 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- 230000003612 virological effect Effects 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 4
- 206010042682 Swelling face Diseases 0.000 claims description 4
- 230000002146 bilateral effect Effects 0.000 claims description 4
- 230000004071 biological effect Effects 0.000 claims description 4
- 238000011010 flushing procedure Methods 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 230000003387 muscular Effects 0.000 claims description 4
- 210000005036 nerve Anatomy 0.000 claims description 4
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 238000009499 grossing Methods 0.000 claims description 3
- 210000000106 sweat gland Anatomy 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 241000270722 Crocodylidae Species 0.000 claims description 2
- 208000036071 Rhinorrhea Diseases 0.000 claims description 2
- 206010039101 Rhinorrhoea Diseases 0.000 claims description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- LNNWVNGFPYWNQE-GMIGKAJZSA-N desomorphine Chemical compound C1C2=CC=C(O)C3=C2[C@]24CCN(C)[C@H]1[C@@H]2CCC[C@@H]4O3 LNNWVNGFPYWNQE-GMIGKAJZSA-N 0.000 claims description 2
- 210000004561 lacrimal apparatus Anatomy 0.000 claims description 2
- 230000036563 plantar hyperhidrosis Effects 0.000 claims description 2
- 210000003079 salivary gland Anatomy 0.000 claims description 2
- 210000003811 finger Anatomy 0.000 claims 2
- 206010059237 Auriculotemporal syndrome Diseases 0.000 claims 1
- 208000004041 Gustatory Sweating Diseases 0.000 claims 1
- 210000003056 antler Anatomy 0.000 claims 1
- 230000007794 irritation Effects 0.000 claims 1
- 210000004237 neck muscle Anatomy 0.000 claims 1
- 230000037392 palmar hyperhidrosis Effects 0.000 claims 1
- 231100000614 poison Toxicity 0.000 claims 1
- 230000007096 poisonous effect Effects 0.000 claims 1
- 210000001991 scapula Anatomy 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 description 21
- 208000014094 Dystonic disease Diseases 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 19
- 239000000243 solution Substances 0.000 description 16
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 230000001225 therapeutic effect Effects 0.000 description 14
- 102000009027 Albumins Human genes 0.000 description 13
- 108010088751 Albumins Proteins 0.000 description 13
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 13
- 229940094657 botulinum toxin type a Drugs 0.000 description 13
- 239000003381 stabilizer Substances 0.000 description 12
- 239000003814 drug Substances 0.000 description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 9
- 229920002674 hyaluronan Polymers 0.000 description 9
- 229960003160 hyaluronic acid Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 229920001184 polypeptide Polymers 0.000 description 9
- 239000003755 preservative agent Substances 0.000 description 9
- 102000004196 processed proteins & peptides Human genes 0.000 description 9
- 108090000765 processed proteins & peptides Proteins 0.000 description 9
- 239000007974 sodium acetate buffer Substances 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 230000002411 adverse Effects 0.000 description 7
- 239000002577 cryoprotective agent Substances 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 239000002202 Polyethylene glycol Substances 0.000 description 6
- 229920001223 polyethylene glycol Polymers 0.000 description 6
- 210000001747 pupil Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000008100 Human Serum Albumin Human genes 0.000 description 5
- 108091006905 Human Serum Albumin Proteins 0.000 description 5
- 102000007562 Serum Albumin Human genes 0.000 description 5
- 108010071390 Serum Albumin Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000008921 facial expression Effects 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 208000035824 paresthesia Diseases 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 208000008238 Muscle Spasticity Diseases 0.000 description 4
- 206010044074 Torticollis Diseases 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000006174 pH buffer Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 150000005846 sugar alcohols Polymers 0.000 description 4
- 206010010904 Convulsion Diseases 0.000 description 3
- 206010018852 Haematoma Diseases 0.000 description 3
- 208000004044 Hypesthesia Diseases 0.000 description 3
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000007385 chemical modification Methods 0.000 description 3
- 230000036461 convulsion Effects 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 230000008451 emotion Effects 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 208000034783 hypoesthesia Diseases 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000036651 mood Effects 0.000 description 3
- 230000007383 nerve stimulation Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 208000018198 spasticity Diseases 0.000 description 3
- 210000003371 toe Anatomy 0.000 description 3
- 108010077805 Bacterial Proteins Proteins 0.000 description 2
- 241000193403 Clostridium Species 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 208000012661 Dyskinesia Diseases 0.000 description 2
- 206010014080 Ecchymosis Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 208000003926 Myelitis Diseases 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- RAHZWNYVWXNFOC-UHFFFAOYSA-N Sulphur dioxide Chemical compound O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 description 2
- 206010043376 Tetanus Diseases 0.000 description 2
- 108010055044 Tetanus Toxin Proteins 0.000 description 2
- 230000021736 acetylation Effects 0.000 description 2
- 238000006640 acetylation reaction Methods 0.000 description 2
- 230000010933 acylation Effects 0.000 description 2
- 238000005917 acylation reaction Methods 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 206010005159 blepharospasm Diseases 0.000 description 2
- 230000000744 blepharospasm Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 206010008129 cerebral palsy Diseases 0.000 description 2
- 201000002866 cervical dystonia Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004209 hair Anatomy 0.000 description 2
- 239000002596 immunotoxin Substances 0.000 description 2
- 208000018197 inherited torticollis Diseases 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 229940124272 protein stabilizer Drugs 0.000 description 2
- 201000003004 ptosis Diseases 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 238000005063 solubilization Methods 0.000 description 2
- 230000007928 solubilization Effects 0.000 description 2
- -1 storage Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- DBTMGCOVALSLOR-UHFFFAOYSA-N 32-alpha-galactosyl-3-alpha-galactosyl-galactose Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(OC2C(C(CO)OC(O)C2O)O)OC(CO)C1O DBTMGCOVALSLOR-UHFFFAOYSA-N 0.000 description 1
- 229940100484 5-chloro-2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- LXAHHHIGZXPRKQ-UHFFFAOYSA-N 5-fluoro-2-methylpyridine Chemical compound CC1=CC=C(F)C=N1 LXAHHHIGZXPRKQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 241000567030 Ampulloclitocybe clavipes Species 0.000 description 1
- 208000031295 Animal disease Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000004130 Blepharoptosis Diseases 0.000 description 1
- 208000019352 Blepharospasm-oromandibular dystonia syndrome Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 208000006274 Brain Stem Neoplasms Diseases 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 241001112695 Clostridiales Species 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 208000011990 Corticobasal Degeneration Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- RXVWSYJTUUKTEA-UHFFFAOYSA-N D-maltotriose Natural products OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1OC1C(O)C(O)C(O)C(CO)O1 RXVWSYJTUUKTEA-UHFFFAOYSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 235000009967 Erodium cicutarium Nutrition 0.000 description 1
- 206010015995 Eyelid ptosis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 229920001612 Hydroxyethyl starch Polymers 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005190 Meige syndrome Diseases 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 208000001738 Nervous System Trauma Diseases 0.000 description 1
- 206010058667 Oral toxicity Diseases 0.000 description 1
- 208000012075 Paroxysmal dystonia Diseases 0.000 description 1
- 206010035628 Pleurothotonus Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 206010067672 Spasmodic dysphonia Diseases 0.000 description 1
- 206010048992 Spinal cord haemorrhage Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000032851 Subarachnoid Hemorrhage Diseases 0.000 description 1
- 208000002667 Subdural Hematoma Diseases 0.000 description 1
- 206010042364 Subdural haemorrhage Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 206010043101 Talipes Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 201000003426 X-linked dystonia-parkinsonism Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- IEJXVRYNEISIKR-UHFFFAOYSA-N apraclonidine Chemical compound ClC1=CC(N)=CC(Cl)=C1NC1=NCCN1 IEJXVRYNEISIKR-UHFFFAOYSA-N 0.000 description 1
- 229960002610 apraclonidine Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000003305 autocrine Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 108700017751 botulinum toxin type C Proteins 0.000 description 1
- 108010069022 botulinum toxin type D Proteins 0.000 description 1
- 108010069023 botulinum toxin type E Proteins 0.000 description 1
- 108010069038 botulinum toxin type F Proteins 0.000 description 1
- 108010069071 botulinum toxin type G Proteins 0.000 description 1
- 210000000133 brain stem Anatomy 0.000 description 1
- 206010006514 bruxism Diseases 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 235000010331 calcium propionate Nutrition 0.000 description 1
- 239000004330 calcium propionate Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- DHNRXBZYEKSXIM-UHFFFAOYSA-N chloromethylisothiazolinone Chemical compound CN1SC(Cl)=CC1=O DHNRXBZYEKSXIM-UHFFFAOYSA-N 0.000 description 1
- 201000011228 clubfoot Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 244000221110 common millet Species 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 229940088679 drug related substance Drugs 0.000 description 1
- 229940098753 dysport Drugs 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 229960004756 ethanol Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000008675 hereditary spastic paraplegia Diseases 0.000 description 1
- 229940050526 hydroxyethylstarch Drugs 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 230000003100 immobilizing effect Effects 0.000 description 1
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- FYGDTMLNYKFZSV-UHFFFAOYSA-N mannotriose Natural products OC1C(O)C(O)C(CO)OC1OC1C(CO)OC(OC2C(OC(O)C(O)C2O)CO)C(O)C1O FYGDTMLNYKFZSV-UHFFFAOYSA-N 0.000 description 1
- 230000034217 membrane fusion Effects 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 208000015001 muscle soreness Diseases 0.000 description 1
- 239000002636 mycotoxin Substances 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 208000008795 neuromyelitis optica Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000418 oral toxicity Toxicity 0.000 description 1
- 201000002851 oromandibular dystonia Diseases 0.000 description 1
- 230000024241 parasitism Effects 0.000 description 1
- 230000001936 parietal effect Effects 0.000 description 1
- 208000013667 paroxysmal dyskinesia Diseases 0.000 description 1
- 230000006320 pegylation Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- DJEHXEMURTVAOE-UHFFFAOYSA-M potassium bisulfite Chemical compound [K+].OS([O-])=O DJEHXEMURTVAOE-UHFFFAOYSA-M 0.000 description 1
- 229940099427 potassium bisulfite Drugs 0.000 description 1
- 235000010259 potassium hydrogen sulphite Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 201000002899 segmental dystonia Diseases 0.000 description 1
- 230000037321 sleepiness Effects 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 201000002849 spasmodic dystonia Diseases 0.000 description 1
- 230000001148 spastic effect Effects 0.000 description 1
- 206010062261 spinal cord neoplasm Diseases 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000023516 stroke disease Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000019635 sulfation Effects 0.000 description 1
- 238000005670 sulfation reaction Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000000966 temporal muscle Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000001018 virulence Effects 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
- 229940018272 xeomin Drugs 0.000 description 1
- FYGDTMLNYKFZSV-BYLHFPJWSA-N β-1,4-galactotrioside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@H](CO)O[C@@H](O[C@@H]2[C@@H](O[C@@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-BYLHFPJWSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Neurosurgery (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US901007P | 2007-12-21 | 2007-12-21 | |
| EP07024961A EP2072039A1 (en) | 2007-12-21 | 2007-12-21 | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| PCT/EP2008/010782 WO2009080272A1 (en) | 2007-12-21 | 2008-12-17 | Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011506511A true JP2011506511A (ja) | 2011-03-03 |
| JP2011506511A5 JP2011506511A5 (enExample) | 2012-01-05 |
Family
ID=39401018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010538453A Pending JP2011506511A (ja) | 2007-12-21 | 2008-12-17 | 副作用を軽減または防止するためのボツリヌス菌毒素複合体の神経毒成分の使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100331259A1 (enExample) |
| EP (2) | EP2072039A1 (enExample) |
| JP (1) | JP2011506511A (enExample) |
| KR (1) | KR20100107475A (enExample) |
| CN (1) | CN101917960A (enExample) |
| AR (1) | AR069806A1 (enExample) |
| AU (1) | AU2008340713A1 (enExample) |
| CA (1) | CA2709644A1 (enExample) |
| IL (1) | IL206423A0 (enExample) |
| MX (1) | MX2010006731A (enExample) |
| RU (1) | RU2010130542A (enExample) |
| WO (1) | WO2009080272A1 (enExample) |
| ZA (1) | ZA201004393B (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016540785A (ja) * | 2013-12-12 | 2016-12-28 | メディ−トックス インク | 新しいボツリヌス毒素製剤の長期持続作用 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10792344B2 (en) * | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
| US9161970B2 (en) * | 2007-12-12 | 2015-10-20 | Allergan, Inc. | Dermal filler |
| US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
| WO2018146550A1 (en) * | 2017-02-10 | 2018-08-16 | De Maio Domingos Mauricio | Methods and systems for preventing, correcting, transforming, and modifying facial, aesthetics, and consulting patients regarding the same |
| DE102019215585B4 (de) * | 2019-10-10 | 2022-02-17 | KCM Egészségügyi és Tudományos Korlátolt Felelösségü Társaság | Verfahren zur prävention von strahlenschäden in humanen drüsen |
| US11241479B2 (en) | 2019-10-18 | 2022-02-08 | Penland Foundation | Treatment methods using botulinum toxins |
| US10973873B1 (en) | 2019-10-18 | 2021-04-13 | Penland Foundation | Treatment of asthma using botulinum toxin |
| US11090371B1 (en) * | 2019-10-18 | 2021-08-17 | Penland Foundation | Treatment of cirrhosis using botulinum toxin |
| US11925677B2 (en) | 2021-07-12 | 2024-03-12 | Penland Foundation | Treatment of diabetes and chronic pancreatitis using botulinum toxin |
| US10967052B1 (en) | 2019-10-18 | 2021-04-06 | Penland Foundation | Treatment of dyslexia using botulinum toxin |
| AU2020365148B2 (en) | 2019-10-18 | 2022-10-27 | Penland Foundation | Botulinum toxin for use in treatment |
| US11738071B2 (en) | 2021-07-12 | 2023-08-29 | Penland Foundation | Treatment of acute and chronic kidney disease |
| US10987411B1 (en) | 2019-10-18 | 2021-04-27 | Penland Foundation | Treatment of chronic obstructive pulmonary disease using botulinum toxin |
| US10960061B1 (en) * | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of amyotrophic lateral sclerosis using botulinum toxin |
| US10960060B1 (en) | 2019-10-18 | 2021-03-30 | Penland Foundation | Treatment of cardiac arrhythmia using botulinum toxin |
| KR102397708B1 (ko) * | 2020-04-29 | 2022-05-16 | 한국화학연구원 | 탄닌산을 포함하는 보툴리눔 독소 약제학적 조성물 |
| CN116096399A (zh) * | 2020-06-03 | 2023-05-09 | 米奥托克斯有限责任公司 | 用于治疗偏头痛病症的区带性和靶向方法和用途 |
| IL298399A (en) * | 2020-06-05 | 2023-01-01 | Merz Pharma Gmbh & Co Kgaa | Treatment of facial wrinkles with the botulinum toxin in high dose and low volume |
| KR102724650B1 (ko) | 2021-07-05 | 2024-11-01 | 주식회사 파마리서치바이오 | 클로스트리디움 보툴리눔 독소 복합체 단백질의 정제방법 |
| KR102724651B1 (ko) | 2021-07-08 | 2024-11-01 | 주식회사 파마리서치바이오 | 비-독소 단백질이 제거된 클로스트리디움 보툴리눔 신경독소 단백질의 정제방법 |
| KR102551301B1 (ko) | 2022-10-28 | 2023-07-03 | 주식회사 파마리서치바이오 | 보툴리눔 독소를 포함하는 안정한 액상 제제 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09507234A (ja) * | 1993-12-28 | 1997-07-22 | アラーガン | 種々の疾病およびそれに伴う疼痛を処置するためのボツリヌス毒素 |
| JPH11507072A (ja) * | 1996-03-27 | 1999-06-22 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ボツリヌス毒素またはボツリヌス神経毒の薬学的組成物および製造方法 |
| JP2003505343A (ja) * | 1999-06-07 | 2003-02-12 | メルツ・ウント・コンパニー・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー | ボツリヌス神経毒を含む治療薬 |
| WO2003082315A1 (fr) * | 2002-03-29 | 2003-10-09 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Remede contre l'hypermyotonie |
| US20040115222A1 (en) * | 2002-09-06 | 2004-06-17 | Michael Kane | Method for reduction of wrinkles |
| US20040126397A1 (en) * | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating various disorders and conditions and associated pain |
| JP2005089336A (ja) * | 2003-09-12 | 2005-04-07 | Tokyo Univ Of Agriculture | Ｄ型ボツリヌス神経毒素の精製法 |
| WO2006020208A2 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition whit a botulinum neurotoxin |
| GB2426702A (en) * | 2004-10-28 | 2006-12-06 | Ipsen Ltd | Pharmaceutical composition comprising botulinum neurotoxin |
| WO2008000490A1 (en) * | 2006-06-29 | 2008-01-03 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of neurotoxic component of botulinum toxin |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5512547A (en) * | 1994-10-13 | 1996-04-30 | Wisconsin Alumni Research Foundation | Pharmaceutical composition of botulinum neurotoxin and method of preparation |
| CA2494241C (en) | 2000-02-08 | 2011-06-14 | Allergan, Inc. | Botulinum toxin pharmaceutical compositions |
| US6503653B2 (en) * | 2001-02-23 | 2003-01-07 | General Motors Corporation | Stamped bipolar plate for PEM fuel cell stack |
| JP3830766B2 (ja) * | 2001-03-09 | 2006-10-11 | 本田技研工業株式会社 | 燃料電池および燃料電池スタック |
| DE102004043009A1 (de) * | 2004-09-06 | 2006-03-23 | Toxogen Gmbh | Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen |
| DE102005019302A1 (de) | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
-
2007
- 2007-12-21 EP EP07024961A patent/EP2072039A1/en not_active Withdrawn
-
2008
- 2008-12-17 US US12/735,144 patent/US20100331259A1/en not_active Abandoned
- 2008-12-17 CN CN2008801218887A patent/CN101917960A/zh active Pending
- 2008-12-17 KR KR1020107016383A patent/KR20100107475A/ko not_active Withdrawn
- 2008-12-17 EP EP08864233A patent/EP2231107A1/en not_active Withdrawn
- 2008-12-17 MX MX2010006731A patent/MX2010006731A/es not_active Application Discontinuation
- 2008-12-17 WO PCT/EP2008/010782 patent/WO2009080272A1/en not_active Ceased
- 2008-12-17 CA CA2709644A patent/CA2709644A1/en not_active Abandoned
- 2008-12-17 JP JP2010538453A patent/JP2011506511A/ja active Pending
- 2008-12-17 RU RU2010130542/15A patent/RU2010130542A/ru not_active Application Discontinuation
- 2008-12-17 AU AU2008340713A patent/AU2008340713A1/en not_active Abandoned
- 2008-12-18 AR ARP080105529A patent/AR069806A1/es not_active Application Discontinuation
-
2010
- 2010-06-16 IL IL206423A patent/IL206423A0/en unknown
- 2010-06-22 ZA ZA2010/04393A patent/ZA201004393B/en unknown
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09507234A (ja) * | 1993-12-28 | 1997-07-22 | アラーガン | 種々の疾病およびそれに伴う疼痛を処置するためのボツリヌス毒素 |
| US20040126397A1 (en) * | 1993-12-28 | 2004-07-01 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating various disorders and conditions and associated pain |
| JPH11507072A (ja) * | 1996-03-27 | 1999-06-22 | ウイスコンシン アラムナイ リサーチ フオンデーシヨン | ボツリヌス毒素またはボツリヌス神経毒の薬学的組成物および製造方法 |
| JP2003505343A (ja) * | 1999-06-07 | 2003-02-12 | メルツ・ウント・コンパニー・ゲゼルシヤフト・ミト・ベシュレンクテル・ハフツング・ウント・コンパニー | ボツリヌス神経毒を含む治療薬 |
| WO2003082315A1 (fr) * | 2002-03-29 | 2003-10-09 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Remede contre l'hypermyotonie |
| US20040115222A1 (en) * | 2002-09-06 | 2004-06-17 | Michael Kane | Method for reduction of wrinkles |
| JP2005089336A (ja) * | 2003-09-12 | 2005-04-07 | Tokyo Univ Of Agriculture | Ｄ型ボツリヌス神経毒素の精製法 |
| WO2006020208A2 (en) * | 2004-07-26 | 2006-02-23 | Merz Pharma Gmbh & Co. Kgaa | Therapeutic composition whit a botulinum neurotoxin |
| GB2426702A (en) * | 2004-10-28 | 2006-12-06 | Ipsen Ltd | Pharmaceutical composition comprising botulinum neurotoxin |
| WO2008000490A1 (en) * | 2006-06-29 | 2008-01-03 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of neurotoxic component of botulinum toxin |
Non-Patent Citations (3)
| Title |
|---|
| JPN5011001794; Ｒ．ＢＥＮＥＣＫＥ ＥＴ ＡＬ．: 'Ａ ＮＥＷ ＢＯＴＵＬＩＮＵＭ ＴＯＸＩＮ ＴＹＰＥ Ａ ＦＲＥＥ ＯＦ ＣＯＭＰＬＥＸＩＮＧ ＰＲＯＴＥＩＮＳ ＦＯＲ ＴＲＥＡＴＭＥＮＴ ＯＦ ＣＥＲＶＩＣＡＬ ＤＹＳＴＯＮＩＡ' ＮＥＵＲＯＬＯＧＹ Ｖ６４, 200506, Ｐ１９４９-１９５１ * |
| JPN5011001795; ＷＯＬＦＧＡＮＧ Ｈ ＪＯＳＴ ＥＴ ＡＬ．: 'ＢＯＴＵＬＩＮＵＭ ＮＥＵＲＯＴＯＸＩＮ ＴＹＰＥ Ａ ＦＲＥＥ ＯＦ ＣＯＭＰＬＥＸＩＮＧ ＰＲＯＴＥＩＮＳ （ＸＥＯＭＩＮＲＴＭ） ＩＮ ＦＯＣＡＬ ＤＹＳＴＯＮＩＡ' ＤＲＵＧＳ Ｖ６７ Ｎ５, 200706, Ｐ６６９-６８３ * |
| JPN5011001796; Ｐ．ＲＯＧＧＥＮＫＡＭＰＥＲ ＥＴ ＡＬ．: 'ＥＦＦＩＣＡＣＹ ＡＮＤ ＳＡＦＥＴＹ ＯＦ Ａ ＮＥＷ ＢＯＴＵＬＩＮＵＭ ＴＯＸＩＮ ＴＹＰＥ Ａ ＦＲＥＥ ＯＦ ＣＯＭＰＬＥＸＩＮＧ ＰＲＯＴＥＩＮＳ ＩＮ ＴＨＥ ＴＲＥＡＴＭＥＮＴ ＯＦ' ＪＯＵＲＮＡＬ ＯＦ ＮＥＵＲＡＬ ＴＲＡＮＳＭＩＳＳＩＯＮ Ｖ１１３, 2006, Ｐ３０３-３１２ * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016540785A (ja) * | 2013-12-12 | 2016-12-28 | メディ−トックス インク | 新しいボツリヌス毒素製剤の長期持続作用 |
| JP2020045360A (ja) * | 2013-12-12 | 2020-03-26 | メディ−トックス インク | 新しいボツリヌス毒素製剤の長期持続作用 |
| JP7121458B2 (ja) | 2013-12-12 | 2022-08-18 | メディトックス インク． | 新しいボツリヌス毒素製剤の長期持続作用 |
| JP2022161932A (ja) * | 2013-12-12 | 2022-10-21 | メディトックス インク． | 新しいボツリヌス毒素製剤の長期持続作用 |
| JP7439187B2 (ja) | 2013-12-12 | 2024-02-27 | メディトックス インク． | 新しいボツリヌス毒素製剤の長期持続作用 |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2010006731A (es) | 2010-08-16 |
| AR069806A1 (es) | 2010-02-17 |
| IL206423A0 (en) | 2010-12-30 |
| KR20100107475A (ko) | 2010-10-05 |
| CN101917960A (zh) | 2010-12-15 |
| CA2709644A1 (en) | 2009-07-02 |
| AU2008340713A1 (en) | 2009-07-02 |
| EP2231107A1 (en) | 2010-09-29 |
| EP2072039A1 (en) | 2009-06-24 |
| RU2010130542A (ru) | 2012-01-27 |
| ZA201004393B (en) | 2011-08-31 |
| WO2009080272A1 (en) | 2009-07-02 |
| US20100331259A1 (en) | 2010-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011506511A (ja) | 副作用を軽減または防止するためのボツリヌス菌毒素複合体の神経毒成分の使用 | |
| JP5897784B2 (ja) | ボツリヌス毒素の神経毒成分の高頻度適用 | |
| KR101095725B1 (ko) | 신경학적 및 신경정신학적 장애의 보툴리눔 독소 처치 | |
| ES2335662T3 (es) | Tratamiento de trastornos y afecciones neuromusculares con diferentes serotipos de botulinum. | |
| ES2238969T3 (es) | Neurotoxinas presinapticas para el tratamiento de cefaleas migrañosas. | |
| RU2743746C2 (ru) | Композиция, содержащая ботулинический токсин | |
| JP2006052227A (ja) | 神経筋疾患および症状を処置するためのボツリヌス毒素組み合わせ | |
| CN112533676A (zh) | 用于抑制cgrp的神经毒素 | |
| JP2010514781A (ja) | Ｈｉｖ−ｔａｔに由来するポリペプチド断片を用いて安定化されるボツリヌス毒素を局所適用及び経皮送達する組成物及び方法 | |
| US7384918B2 (en) | Botulinum toxin for treating muscle contracture | |
| CN109562148A (zh) | 用色氨酸或酪氨酸稳定的液体神经毒素制剂 | |
| JP2021505570A (ja) | 高い応答率及び長い効果の持続期間を有する注射可能なボツリヌス毒素製剤及びその使用方法 | |
| WO2011160826A1 (en) | Botulinum toxin therapy | |
| US20120251574A1 (en) | Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions | |
| US20120251575A1 (en) | Endopeptidase Treatment of Involuntary Movement Disorders | |
| ES2665285T3 (es) | Tratamiento temprano y prevención del aumento de la tonicidad muscular | |
| HK1151217A (en) | Use of a neurotoxic component of a clostridium botulinum toxin complex to reduce or prevent side effects | |
| RU2832647C1 (ru) | Композиция, содержащая ботулинический токсин | |
| Gupta | Craniofacial Applications of Botulinum Toxin: A Review of Literature | |
| Chaurasia et al. | Craniofacial Applications of Botulinum toxin: An Update | |
| HK1131739A (en) | High frequency application of neurotoxic component of botulinum toxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111109 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111109 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130729 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130813 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140128 |